Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Discovery

Background:

• Patient-derived organoids (PDOs) are increasingly vital for therapeutic screening, offering greater physiological relevance than traditional cell lines.
• Challenges persist in fully leveraging PDOs for drug discovery and development.

Purpose of the Study:

• To summarize advancements in PDO development and culture models.
• To discuss PDO applications in therapy screening for cancer treatment.
• To explore data analysis tools and future perspectives for PDOs in drug development.

Main Methods:

• Review of materials engineering and microfabrication technologies (e.g., organs-on-a-chip, droplet microfluidics).
• Discussion of PDO applications in diverse therapeutic screening requirements.
• Introduction of tools for organoid and microenvironment data processing and analysis.

Main Results:

• Recent advancements enhance PDO culture models using innovative engineering techniques.
• PDOs show promise in overcoming bottlenecks in cancer treatment screening.
• New tools improve data analysis for enhanced organoid readouts.

Conclusions:

• PDOs represent a significant improvement for drug discovery and personalized cancer therapy.
• Continued development in materials engineering and data analysis will further unlock PDO potential.
• Addressing current challenges is crucial for the widespread clinical adoption of PDOs in drug development.